FXI−/−mice have normal tail bleeding times but show decreased clot formation at injury sites of arterial or venous.257Likewise, treatment of rodent or rabbit models with FXI antisense oligonucleotides (FXI-ASO) or anti-FXI antibodies has shown resistance to experimentally induced thrombosis and a low risk of bleeding complications.258, 259Different strategies targeting FXI/FXIa for antithrombotic therapy are under development in clinical trials. This evidence concerns the gene F11 and deep vein thrombosis.